News

. . .

		AboutBoard of directors
Management
Who we are
We build...CompaniesOverview
Internal Portfolio
Companies we’ve helped build
Accelerator
EcosystemsOverview
Innovation Centres
adMare Community
TalentOverview
Executive Institute
BIS Program
Experiential  Learning
adMare Institute
News
Events
CareersCulture
Open positions
Press Room
Contact us
Newsletter

	

			Terms and conditions
    
Français

		
adMare

News
vertical
adMare newsadMare insightsPortfolio companiesadMare AcademyAccelerator companies

						
						September 17 2025
Portfolio companies						
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
Read

						
						September 09 2025
Portfolio companies						
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
Read

						
						September 08 2025
Portfolio companies						
Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025
Read

						
						July 10 2025
Portfolio companies						
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
Read

						
						June 11 2025
Portfolio companies						

Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors

Read

						
						May 27 2025
Portfolio companies						

Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC

Read

						
						May 01 2025
Portfolio companies						

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

Read

						
						April 10 2025
Portfolio companies						

Two key experts joining Find Therapeutics to accelerate the development of FTX-101

Read

						
						February 19 2025
Portfolio companies						
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens
Read

						
						December 02 2024
Portfolio companies						
KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications
Read

						
						November 21 2024
Portfolio companies						
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Read

						
						November 15 2024
Portfolio companies						
Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
Read
  1  2  3  4  5  6  7
Newsletter

Stay up to date on the

latest adMare news
Subscribe
Français
Vancouver Innovation Centre2405 Wesbrook Mall

Vancouver, British Columbia, Canada

V6T 1Z3
T. 604.827.1147
Toronto OfficeMaRS Centre, West Tower

661 University Ave., Suite 415

Toronto, Ontario, Canada

M5G 1M1
T. 416.673.8100
Montreal Innovation Centre7171 Frederick-Banting

Montréal, Québec, Canada

H4S 1Z9
T. 514.375.3334
We

	build ...
Companies
Ecosystems
Talent
Who we are
adMare Institute
News
Events
Careers
Newsletter
Contact Us
Press Room
  
adMare

Community
Français
adMare BioInnovations Année all rights reserved - Privacy policy
Website by Riposte
 




  <img height="1" width="1" style="display:none" alt=""
       src="https://px.ads.linkedin.com/collect/?pid=7577452&fmt=gif" />


                
                    Powered by 
                    
                
            

adMare News

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens

KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Newsletter

Stay up to date on the latest adMare news

Vancouver Innovation Centre

T. 604.827.1147

Toronto Office

T. 416.673.8100

Montreal Innovation Centre

T. 514.375.3334

adMare
News

Stay up to date on the
latest adMare news